SYBIL – MIT Jameel Clinic

Our Mission

Lung cancer is the leading cause of cancer-related deaths worldwide. While smoking is the leading cause of lung cancer, lung cancer rates among nonsmokers are on the rise.

Every person has the right to know their risk of developing cancer — Sybil is a deep learning model that accurately predicts a patient’s risk of lung cancer up to six years in advance from analyzing a low-dose CT scan, ensuring that lung cancer is detected in its earliest stages.

25 Hospitals

11 Countries

120K+ LDCT scans validated

Thanks to the support of Wellcome Trust, we have been able to expand the deployment of Sybil to include hospitals serving under-resourced regions.

Try Sybil

Collaborate with us

Hospitals around the world have installed Sybil with some publishing independent research on Sybil.

Our Sybil Lung Cancer Consortium aims to study the deployment of Sybil to change screening policies and transform lung health.

We welcome hospitals to join our Hospital Network.

How does Sybil work?

Sybil is named after the divine oracles of ancient Greece, known as “sibyls.”

The deep learning model assigns a personalized risk score to the LDCT scan, helping clinicians determine when a patient should return for their next screening, or if the patient can avoid unnecessary screening.

Evaluate Sybil’s performance.

Sybil researchers pose for a photo in front of an CT scanner

The team behind Sybil

Combining leading expertise in AI and clinical practice, researchers at MIT and clinicians at Mass General Brigham joined forces to build Sybil.

Using this technology, we hope to improve early detection rates of lung cancer while reducing the burden on healthcare systems.

The scale and computational power needed for bold ideas to work is not possible without the support of grants, foundations, and donors. Your support would enable MIT Jameel Clinic to make a better, healthier future for all.

Give Now

We're in the process of running Sybil on all of our lung screening patients. We're particularly interested in whether Sybil will flag patients with pulmonary nodules as high risk and if they should they be followed up with more frequently. Mary Pasquinelli, APRN, FNP-BC
University of Illinois
Division of Pulmonary, Critical Care, Sleep, and Allergy at UI Health

In Chile, we do not yet have a national lung cancer screening strategy…we are developing a targeted screening program in Northern Chile, focused on high-risk populations within the mining industry. To evaluate this approach within the Latin American context, we are collaborating with countries that have implemented lung cancer screening programs, such as the LUCAS Project in Argentina. Dr. Arnaldo Marín, MD, PhD
Assistant Professor
University of Chile